EP3947389A4 - Polymorphes d'un inhibiteur de kinase, compositions pharmaceutiques contenant un tel composé, procédés de préparation et utilisations - Google Patents

Polymorphes d'un inhibiteur de kinase, compositions pharmaceutiques contenant un tel composé, procédés de préparation et utilisations Download PDF

Info

Publication number
EP3947389A4
EP3947389A4 EP20783939.0A EP20783939A EP3947389A4 EP 3947389 A4 EP3947389 A4 EP 3947389A4 EP 20783939 A EP20783939 A EP 20783939A EP 3947389 A4 EP3947389 A4 EP 3947389A4
Authority
EP
European Patent Office
Prior art keywords
polymorphs
applications
compound
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20783939.0A
Other languages
German (de)
English (en)
Other versions
EP3947389A1 (fr
Inventor
Xiaodong Wang
Weihe Zhang
Xiangyong LIU
Changlong Han
Zongquan Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
University of North Carolina at Chapel Hill
Meryx Inc
Original Assignee
Betta Pharmaceuticals Co Ltd
University of North Carolina at Chapel Hill
Meryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd, University of North Carolina at Chapel Hill, Meryx Inc filed Critical Betta Pharmaceuticals Co Ltd
Publication of EP3947389A1 publication Critical patent/EP3947389A1/fr
Publication of EP3947389A4 publication Critical patent/EP3947389A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20783939.0A 2019-04-02 2020-04-01 Polymorphes d'un inhibiteur de kinase, compositions pharmaceutiques contenant un tel composé, procédés de préparation et utilisations Pending EP3947389A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962828055P 2019-04-02 2019-04-02
PCT/US2020/026167 WO2020205967A1 (fr) 2019-04-02 2020-04-01 Polymorphes d'un inhibiteur de kinase, compositions pharmaceutiques contenant un tel composé, procédés de préparation et utilisations

Publications (2)

Publication Number Publication Date
EP3947389A1 EP3947389A1 (fr) 2022-02-09
EP3947389A4 true EP3947389A4 (fr) 2023-01-11

Family

ID=72667038

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20783939.0A Pending EP3947389A4 (fr) 2019-04-02 2020-04-01 Polymorphes d'un inhibiteur de kinase, compositions pharmaceutiques contenant un tel composé, procédés de préparation et utilisations

Country Status (10)

Country Link
US (1) US20220162214A1 (fr)
EP (1) EP3947389A4 (fr)
JP (1) JP2022522539A (fr)
KR (1) KR20220104637A (fr)
CN (1) CN114127071B (fr)
AU (1) AU2020256186A1 (fr)
CA (1) CA3146343A1 (fr)
IL (1) IL286934A (fr)
TW (1) TW202102508A (fr)
WO (1) WO2020205967A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102063098B1 (ko) * 2011-10-03 2020-01-08 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 암 치료를 위한 피롤로피리미딘 화합물
WO2015157122A1 (fr) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Composés de pyrazolopyrimidine spécifiques de mertk
WO2017062797A1 (fr) * 2015-10-07 2017-04-13 The University Of North Carolina At Chapel Hill Méthodes de traitement de tumeurs
WO2019006548A1 (fr) * 2017-07-04 2019-01-10 Trillium Therapeutics Inc. Composés de 2,4-diaminopyrimidine fluorés utilisés en tant qu'inhibiteurs de la tyrosine kinase mer (mertk) et leurs utilisations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIPUL SARMA ET AL: "Solid forms of pharmaceuticals: Polymorphs, salts and co-crystals", KOREAN J. CHERM. ENG., vol. 28, no. 2, 1 January 2011 (2011-01-01), pages 315 - 322, XP055402417, DOI: 10.1007/s11814-010-0520-0 *
See also references of WO2020205967A1 *
ZHANG WEIHE ET AL: "Supplemental Information- UNC2025, a potent and orally bioavailable Mer/Flt 3 dual inhibitor", JOURNAL OF MEDICINAL CHEMISTRY, 28 August 2014 (2014-08-28), pages 1 - 17, XP093005052, Retrieved from the Internet <URL:https://pubs.acs.org/doi/suppl/10.1021/jm500749d/suppl_file/jm500749d_si_001.pdf> [retrieved on 20221205] *
ZHANG WEIHE ET AL: "UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 16, 6 August 2014 (2014-08-06), US, pages 7031 - 7041, XP093005047, ISSN: 0022-2623, DOI: 10.1021/jm500749d *

Also Published As

Publication number Publication date
IL286934A (en) 2021-10-31
EP3947389A1 (fr) 2022-02-09
CN114127071B (zh) 2024-03-22
KR20220104637A (ko) 2022-07-26
CN114127071A (zh) 2022-03-01
AU2020256186A1 (en) 2021-11-04
WO2020205967A1 (fr) 2020-10-08
CA3146343A1 (fr) 2020-10-08
JP2022522539A (ja) 2022-04-19
TW202102508A (zh) 2021-01-16
US20220162214A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
EP3914252A4 (fr) Composition pharmaceutique du nilotinib
EP4071149A3 (fr) Composés hétérocycliques et leurs utilisations
EP3797109A4 (fr) Composés hétérocycliques utilisés en tant qu&#39;inhibiteurs de kinase, compositions comprenant le composé hétérocyclique, et leurs procédés d&#39;utilisation
EP3873905A4 (fr) Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu&#39;inhibiteurs de kinase atr
EP3502105B8 (fr) Forme polymorphe d&#39;un composé inhibiteur de kinase, composition pharmaceutique le contenant, son procédé de préparation et son utilisation
EP3974422A4 (fr) Composé utilisé comme inhibiteur de kinase ret et son utilisation
EP3417861A4 (fr) Composition pharmaceutique contenant un inhibiteur de janus kinase (jak) ou un sel pharmaceutiquement acceptable de celui-ci
EP3768267A4 (fr) Composés inhibiteurs de kinase, compositions et procédés d&#39;utilisation
EP3929182A4 (fr) Inhibiteur de kinase multi-cibles, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
EP3880671A4 (fr) Nouveau composé utilisé en tant qu&#39;inhibiteur de protéine kinase, et composition pharmaceutique le comprenant
EP3982949A4 (fr) Inhibiteurs de sarm1
EP3980011A4 (fr) Inhibiteurs de sarm1
EP3906233A4 (fr) Composés inhibiteurs de kinase, compositions et procédés d&#39;utilisation
EP3906028A4 (fr) Composés inhibiteurs de kinase, compositions et méthodes d&#39;utilisation
EP3749646A4 (fr) Composés hétéroaryle utilisés en tant qu&#39;inhibiteur de kinase
EP3967696A4 (fr) Composé utilisé comme inhibiteur de kinase et son application
EP4098258A4 (fr) Utilisation pharmaceutique d&#39;un composé à base de cétoamide
EP3960741A4 (fr) Composés de quinoléine et compositions pharmaceutiques et leurs utilisations
EP4056558A4 (fr) Composé d&#39;indazole, composition pharmaceutique de celui-ci et ses applications
EP4119553A4 (fr) Composé utilisé comme inhibiteur de kinase et son utilisation
EP4031182A4 (fr) Compositions contenant des composés mimétiques d&#39;endocannabinoïdes et anti-inflammatoires, leurs méthodes de préparation et leurs utilisations
EP3978492A4 (fr) Composé bicyclique en tant qu&#39;inhibiteur de la kinase rip-1 et son application
EP4071146A4 (fr) Composé biaryle utilisé comme inhibiteur de kinase pan-raf
EP4015002A4 (fr) Composition pharmaceutique orale contenant un composé hétérocyclique
EP4009962A4 (fr) Compositions de trofinétide

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221213

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20221207BHEP

Ipc: A61K 45/06 20060101ALI20221207BHEP

Ipc: A61K 31/519 20060101ALI20221207BHEP

Ipc: C07D 487/04 20060101AFI20221207BHEP